The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.